DARA BioSciences, Inc. – Product Pipeline Review – H2 2011

Document Sample
DARA BioSciences, Inc. – Product Pipeline Review – H2 2011 Powered By Docstoc
					   DARA BioSciences, Inc. – Product Pipeline Review –
                       H2 2011
                                                                                          Reference Code: GMDHC01762CDB

                                                                                                 Publication Date: NOV 2011




DARA BioSciences, Inc. – Product Pipeline Review – H2 2011                                  GMDHC01762CDB / Published NOV 2011

© Global Markets Direct. This report is a licensed product and is not to be photocopied                                 Page(1)
DARA BioSciences, Inc. – Product Pipeline Review




Ta b le o f Co n te n ts
Table of Contents ..................................................................................................................................................................................................... 2
      List of Tables...................................................................................................................................................................................................... 4
      List of Figures .................................................................................................................................................................................................... 5
DARA BioSciences, Inc. Snapshot ........................................................................................................................................................................... 6
      DARA BioSciences, Inc. Overview ..................................................................................................................................................................... 6
      Key Information .................................................................................................................................................................................................. 6
      Key Facts ........................................................................................................................................................................................................... 6
DARA BioSciences, Inc. – Research and Development Overview ............................................................................................................................ 7
      Key Therapeutic Areas ....................................................................................................................................................................................... 7
DARA BioSciences, Inc. – Pipeline Review .............................................................................................................................................................. 9
      Pipeline Products by Stage of Development ....................................................................................................................................................... 9
      DARA BioSciences, Inc. – Pipeline Products Glance.........................................................................................................................................10
      DARA BioSciences, Inc. Clinical Stage Pipeline Products .................................................................................................................................10
            Phase II Products/Combination Treatment Modalities .................................................................................................................................10
      DARA BioSciences, Inc.–Early Stage Pipeline Products ...................................................................................................................................11
            Pre-Clinical Products/Combination Treatment Modalities ............................................................................................................................11
            Discovery Products/Combination Treatment Modalities ..............................................................................................................................12
DARA BioSciences, Inc. – Drug Profiles ..................................................................................................................................................................13
      DB160 ...............................................................................................................................................................................................................13
            Product Description ....................................................................................................................................................................................13
            Mechanism of Action...................................................................................................................................................................................13
            R&D Progress .............................................................................................................................................................................................13
      DB200 ...............................................................................................................................................................................................................14
            Product Description ....................................................................................................................................................................................14
            Mechanism of Action...................................................................................................................................................................................14
            R&D Progress .............................................................................................................................................................................................14
      DB900 ...............................................................................................................................................................................................................15
            Product Description ....................................................................................................................................................................................15
            Mechanism of Action...................................................................................................................................................................................15
            R&D Progress .............................................................................................................................................................................................15
      DB959 ...............................................................................................................................................................................................................16
            Product Description ....................................................................................................................................................................................16
            Mechanism of Action...................................................................................................................................................................................16
            R&D Progress .............................................................................................................................................................................................16
      KRN5500 ..........................................................................................................................................................................................................17
            Product Description ....................................................................................................................................................................................17
            Mechanism of Action...................................................................................................................................................................................17
            R&D Progress .............................................................................................................................................................................................17
DARA BioSciences, Inc. – Pipeline Analysis ............................................................................................................................................................18
      DARA BioSciences, Inc. – Pipeline Products by Therapeutic Class ...................................................................................................................18
      DARA BioSciences, Inc. - Pipeline Products By Target .....................................................................................................................................19
      DARA BioSciences, Inc. – Pipeline Products by Route of Administration ..........................................................................................................20
      DARA BioSciences, Inc. – Pipeline Products by Molecule Type ........................................................................................................................21
DARA BioSciences, Inc. – Recent Pipeline Updates...............................................................................................................................................22
DARA BioSciences, Inc. - Dormant Projects ............................................................................................................................................................24
DARA BioSciences, Inc. - Discontinued Pipeline Products ......................................................................................................................................25




DARA BioSciences, Inc. – Product Pipeline Review – H2 2011                                                                                                  GMDHC01762CDB / Published NOV 2011

©Global Markets Direct.. This report is a licensed product and is not to be photocopied                                                                                                                                Page(2)
DARA BioSciences, Inc. – Product Pipeline Review



     Discontinued Pipeline Product Profiles ..............................................................................................................................................................25
           PT-100........................................................................................................................................................................................................25
           PT-100 + Cisplatin ......................................................................................................................................................................................25
           Talabostat + Docetaxel ...............................................................................................................................................................................26
           Talabostat + Gemcitabine ...........................................................................................................................................................................26
           Talabostat + Pemetrexed Disodium ............................................................................................................................................................26
           Talabostat + Rituximab ...............................................................................................................................................................................27
DARA BioSciences, Inc. – Company Statement ......................................................................................................................................................28
DARA BioSciences, Inc. – Locations And Subsidiaries ............................................................................................................................................32
     Head Office .......................................................................................................................................................................................................32
     Other Locations & Subsidiaries .........................................................................................................................................................................32
Recent Developments .............................................................................................................................................................................................33
           Mar 30, 2009: DARA BioSciences Presents Abstracts For DB959 At American Diabetes Association Scientific Sessions ..........................33
           Mar 29, 2011: DARA Reports Promising Findings From Phase II Study Of KRN5500 at ADEPT ................................................................33
           Jun 28, 2011: DARA BioSciences Presents Positive Results Of Phase I Study For DB959 At American Diabetes Association Scientific
           Session.......................................................................................................................................................................................................34
           Apr 27, 2010: DARA Partners With Division Of Cancer Prevention, National Cancer Institute For Clinical Development Of KRN5500 ........35
           Mar 26, 2010: DARA BioSciences Initiates Phase I Clinical Study Of DB959 For Treatment Of Type 2 Diabetes .......................................35
           Feb 22, 2010: DARA BioSciences' Clinical Study Results For KRN5500 Selected For Presentation At CHI's Annual 'Targeting Pain with
           Novel Therapeutics" Meeting ......................................................................................................................................................................36
           Jun 21, 2011: DARA BioSciences To Present Positive Results Of DB959 Phase I Study At Upcoming 71st ADA Scientific Sessions ........36
           Apr 21, 2011: DARA To Present Results Of DB959 Phase I Study At 71st ADA Scientific Sessions ...........................................................37
           Aug 18, 2011: DARA BioSciences Receives Fast Track Designation From FDA For KRN5500 For Treatment Of Chemotherapy-Induced
           Neuropathic Pain In Patients With Cancer ..................................................................................................................................................37
           Sep 15, 2011: DARA BioSciences To Present Positive Results Of KRN5500 Phase II Study At 5th Annual Therapeutics Summit .............38
           Sep 15, 2009: DARA BioSciences Presents Phase 2a Study Results For KRN5500 At the "12th International Conference On The
           Mechanisms And Treatment Of Neuropathic Pain" Meeting ........................................................................................................................38
           Dec 14, 2010: DARA BioSciences Reports Positive Phase II Data Of KRN5500 In Neuropathic Pain .........................................................39
           Jul 14, 2009: DARA BioSciences Releases Promising Preclinical Data For DB959 For Type 2 Diabetes . .................................................39
           Oct 10, 2011: DARA BioSciences Announces KRN5500 Demonstrated Significant Decrease In Intensity Of Neuropathic Pain In Patients
         
				
DOCUMENT INFO
Description: DARA BioSciences, Inc. – Product Pipeline Review – H2 2011 Summary Global Market Direct’s pharmaceuticals report, “DARA BioSciences, Inc. - Product Pipeline Review - H2 2011” provides data on the DARA BioSciences, Inc.’s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects. This report is built using data and information sourced from Global Markets Direct’s proprietary databases, DARA BioSciences, Inc.’s corporate website, SEC filings, investor presentations and featured press releases, both from DARA BioSciences, Inc. and industry-specific third party sources, put together by Global Markets Direct’s team. Scope - DARA BioSciences, Inc. - Brief DARA BioSciences, Inc. overview including business description, key information and facts, and its locations and subsidiaries. - Review of current pipeline of DARA BioSciences, Inc. human therapeutic division. - Overview of pipeline therapeutics across various therapy areas. - Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities, across the globe. - Product profiles for late stage and clinical stage products of DARA BioSciences, Inc. with complete description of the product’s developmental history, mechanism of action, therapeutic class, target and major milestones. - Recent updates of the DARA BioSciences, Inc.’s pipeline in the last quarter. - Key discontinued and dormant projects. - Latest news and deals relating to the products. Reasons to buy - Evaluate DARA BioSciences, Inc.’s strategic position with total access to detailed information on its product pipeline. - Assess the growth potential of DARA BioSciences, Inc. in its therapy areas of focus. - Identify new drug targets and therapeutic classes in the DARA BioSciences, Inc.’s R&D portfolio and develop key strategic initiatives to reinfo
BUY THIS DOCUMENT NOW PRICE: $500 100% MONEY BACK GUARANTEED
PARTNER GlobalMarketsDirect
Global Markets Direct is a leading provider of global business intelligence and market analysis. It publishes a range of high quality company and market reports created by its large research and analysis capability and drawing from its extensive unique databases of industry-specific information. Global Markets Direct has a broad range of coverage over key market segments. It has a global scope, covering a broad range of countries constituting more than 90% of global revenues in each of the industries it covers. With a large dedicated research and analysis capability, Global Markets Direct employs rigorous primary and secondary research techniques in developing unique data sets and research materials. Its status as an independent research company allows Analysts to conduct trade interviews with key industry players. Access to unique databases of in-house market information further strengthens research and analysis capabilities. Materials are reviewed shaped by an expert panel of leading industry figures and representatives from key players in the relevant industries